WG
LGND icon

Winton Group’s Ligand Pharmaceuticals LGND Stock Holding History

Winton Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-36,273
Closed -$2.53M – 1544
2020
Q2 		$2.53M Sell
36,273
-23,006
-39% -$1.46M 0.07% 531
2020
Q1 		$2.69M Buy
59,279
+7,755
+15% +$440K 0.07% 468
2019
Q4 		$3.35M Buy
51,524
+24,170
+88% +$1.62M 0.05% 606
2019
Q3 		$1.7M Buy
+27,354
New +$1.72M 0.02% 631
2018
Q2 		– Sell
-11,239
Closed -$1.16M – 1104
2018
Q1 		$1.16M Buy
+11,239
New +$1.11M 0.03% 459

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Winton Group's LGND Position: Q3 2020 in Review

Winton Group sold out of Ligand Pharmaceuticals (LGND) in Q3 2020, closing a stake of 36,273 shares — an estimated $2.53M sold.

Winton Group first reported a position in LGND in Q1 2018 and held it in 5 quarters. The position peaked at $3.35M in Q4 2019. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

  • Winton Group reported no remaining Ligand Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Winton Group sold 36,273 Ligand Pharmaceuticals shares in Q3 2020, an estimated $2.53M.
  • Winton Group first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • Winton Group's Ligand Pharmaceuticals position peaked at $3.35M in Q4 2019.
  • 252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on Winton Group's 13F filing for Q3 2020, filed 30 Oct 2020.